A significant portion of not just the cost but the lead time of creating new medical devices is the repeated requirements for biocompatibility testing, in particular for class 2 and 3 implants. Most companies are re-qualifying material from a supplier that has already been tested a dozen times by other companies. As a part of medical device submissions, require companies to submit the biocompatibility study to a public database such that new companies can leverage the results if the use of the material can be justified to be substantially similar to another device. This sort of justification is already used to justify not re-running other safety testing via similar on-market devices to avoid expensive clinical studies